checkAd
    Algernon Pharmaceuticals Registered (A) (Old) Aktie
    0,0351
     
    USD
    -6,25 %
    -0,0023 USD
    Letzter Kurs 24.11.21 Nasdaq OTC
    ISIN: CA01559R1038 · WKN: A2PEGU · Kanada

    Neueste Nachrichten

    Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
    24.04.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
    11.04.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
    01.04.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
    27.03.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
    31.01.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
    11.01.24 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces Closing of Private Placement
    27.12.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces Increase to Private Placement
    27.12.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
    30.11.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
    22.11.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
    08.11.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)
    Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
    06.09.23 · globenewswire · Algernon Pharmaceuticals Registered (A) (Old)